BACKGROUND: The debilitating effects of chronic glucocorticoids excess are well-known, but comparatively little is understood about the role of acute cortisol. Indirect evidence in rodents suggests that acute cortisone could selectively increase some forms of long-duration aversive states, such as "anxiety," but not relatively similar, briefer aversive states, such as "fear." However, no prior experimental studies in humans consider the unique effects of cortisol on anxiety and fear, using well-validated methods for eliciting these two similar but dissociable aversive states. The current study examines these effects, as instantiated with short- and long-duration threats. METHODS:Healthy volunteers (n = 18) receivedplacebo or a low (20 mg) or a high (60 mg) dose of hydrocortisone in a double-blind crossover design. Subjects were exposed repeatedly to three 150-sec duration conditions: no shock; predictable shocks, in which shocks were signaled by a short-duration threat cue; and unpredictable shocks. Aversive states were indexed by acoustic startle. Fear was operationally defined as the increase in startle reactivity during the threat cue in the predictable condition (fear-potentiated startle). Anxiety was operationally defined as the increase in baseline startle from the no shock to the two threat conditions (anxiety-potentiated startle). RESULTS:Hydrocortisone affected neither baseline nor short-duration, fear-potentiated startle but increased long-duration anxiety-potentiated startle. CONCLUSIONS: These results suggest that hydrocortisone administration in humans selectively increases anxiety but not fear. Possible mechanisms implicated are discussed in light of prior data in rodents. Specifically, hydrocortisone might increase anxiety via sensitization of corticotrophin-releasing hormones in the bed nucleus of the stria terminalis.
RCT Entities:
BACKGROUND: The debilitating effects of chronic glucocorticoids excess are well-known, but comparatively little is understood about the role of acute cortisol. Indirect evidence in rodents suggests that acute cortisone could selectively increase some forms of long-duration aversive states, such as "anxiety," but not relatively similar, briefer aversive states, such as "fear." However, no prior experimental studies in humans consider the unique effects of cortisol on anxiety and fear, using well-validated methods for eliciting these two similar but dissociable aversive states. The current study examines these effects, as instantiated with short- and long-duration threats. METHODS: Healthy volunteers (n = 18) received placebo or a low (20 mg) or a high (60 mg) dose of hydrocortisone in a double-blind crossover design. Subjects were exposed repeatedly to three 150-sec duration conditions: no shock; predictable shocks, in which shocks were signaled by a short-duration threat cue; and unpredictable shocks. Aversive states were indexed by acoustic startle. Fear was operationally defined as the increase in startle reactivity during the threat cue in the predictable condition (fear-potentiated startle). Anxiety was operationally defined as the increase in baseline startle from the no shock to the two threat conditions (anxiety-potentiated startle). RESULTS:Hydrocortisone affected neither baseline nor short-duration, fear-potentiated startle but increased long-duration anxiety-potentiated startle. CONCLUSIONS: These results suggest that hydrocortisone administration in humans selectively increases anxiety but not fear. Possible mechanisms implicated are discussed in light of prior data in rodents. Specifically, hydrocortisone might increase anxiety via sensitization of corticotrophin-releasing hormones in the bed nucleus of the stria terminalis.
Authors: Marianne B Müller; Stephan Zimmermann; Inge Sillaber; Thomas P Hagemeyer; Jan M Deussing; Peter Timpl; Michael S D Kormann; Susanne K Droste; Ralf Kühn; Johannes M H M Reul; Florian Holsboer; Wolfgang Wurst Journal: Nat Neurosci Date: 2003-09-14 Impact factor: 24.884
Authors: Amanda Aerni; Rafael Traber; Christoph Hock; Benno Roozendaal; Gustav Schelling; Andreas Papassotiropoulos; Roger M Nitsch; Ulrich Schnyder; Dominique J-F de Quervain Journal: Am J Psychiatry Date: 2004-08 Impact factor: 18.112
Authors: Andrew H Kemp; Marcus A Gray; Richard B Silberstein; Stuart M Armstrong; Pradeep J Nathan Journal: Neuroimage Date: 2004-07 Impact factor: 6.556
Authors: Liisa Hantsoo; Sara Kornfield; Claudia Iannelli; Jessica Podcasy; David Metzger; Mary D Sammel; C Neill Epperson Journal: J Behav Med Date: 2019-03-19
Authors: Mark J Niciu; Daniel C Mathews; Allison C Nugent; Dawn F Ionescu; Maura L Furey; Erica M Richards; Rodrigo Machado-Vieira; Carlos A Zarate Journal: Depress Anxiety Date: 2013-12-18 Impact factor: 6.505
Authors: Kimberly H Wood; Muriah D Wheelock; Joshua R Shumen; Kenton H Bowen; Lawrence W Ver Hoef; David C Knight Journal: Neuroimage Date: 2015-07-03 Impact factor: 6.556
Authors: Christian Grillon; Elizabeth Hale; Lynne Lieberman; Andrew Davis; Daniel S Pine; Monique Ernst Journal: Neuropsychopharmacology Date: 2015-03-13 Impact factor: 7.853
Authors: Balaji Krishnan; Michael T Scott; Sebastian Pollandt; Bradley Schroeder; Alexander Kurosky; Patricia Shinnick-Gallagher Journal: Neurobiol Learn Mem Date: 2015-12-31 Impact factor: 2.877